| Title |
Clonazepam for neuropathic pain and fibromyalgia in adults
|
|---|---|
| Published in |
Cochrane database of systematic reviews, May 2012
|
| DOI | 10.1002/14651858.cd009486.pub2 |
| Pubmed ID | |
| Authors |
Ruth Corrigan, Sheena Derry, Philip J Wiffen, R Andrew Moore |
| Abstract |
Antiepileptic drugs have been used in pain management since the 1960s; some have shown efficacy in treating different neuropathic pain conditions. Clonazepam, a benzodiazepine, is an established antiepileptic drug, but its place in the treatment of neuropathic pain is unclear. |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 7 | 39% |
| Canada | 2 | 11% |
| Colombia | 1 | 6% |
| Germany | 1 | 6% |
| Spain | 1 | 6% |
| France | 1 | 6% |
| United States | 1 | 6% |
| Sweden | 1 | 6% |
| Unknown | 3 | 17% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 78% |
| Practitioners (doctors, other healthcare professionals) | 2 | 11% |
| Scientists | 2 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 170 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 1% |
| Germany | 2 | 1% |
| Spain | 1 | <1% |
| Australia | 1 | <1% |
| Unknown | 164 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 31 | 18% |
| Student > Bachelor | 21 | 12% |
| Researcher | 16 | 9% |
| Student > Postgraduate | 15 | 9% |
| Student > Doctoral Student | 11 | 6% |
| Other | 31 | 18% |
| Unknown | 45 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 74 | 44% |
| Nursing and Health Professions | 15 | 9% |
| Neuroscience | 7 | 4% |
| Psychology | 6 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
| Other | 15 | 9% |
| Unknown | 48 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 September 2022.
All research outputs
#2,180,327
of 25,457,297 outputs
Outputs from Cochrane database of systematic reviews
#4,528
of 11,499 outputs
Outputs of similar age
#12,932
of 176,582 outputs
Outputs of similar age from Cochrane database of systematic reviews
#47
of 179 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,582 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 179 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.